A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

365

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

April 25, 2025

Study Completion Date

April 25, 2025

Conditions
Genital Herpes
Interventions
BIOLOGICAL

mRNA-1608

Sterile liquid for injection

BIOLOGICAL

BEXSERO

A vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B.

Trial Locations (23)

14609

Rochester Clinical Research, Rochester

23606

Health Research of Hampton Roads, Newport News

27612

M3 Wake Research, Inc., Raleigh

32055

Multi-Specialty Research Associates, Inc., Lake City

33173

Suncoast Research Associates, LLC, Miami

35218

Accel Clinical Sites Network - Cahaba Medical Care, Birmingham

44122

Velocity Clinical Research Cleveland, Beachwood

48076

DM Clinical Research, Southfield

66219

Johnson County Clin-Trials (JCCT), Lenexa

67114

Alliance for Multispecialty Research, LLC, Newton

68701

Velocity Clinical Research, Norfolk

68803

Velocity Clinical Research, Grand Island

70125

Research Works, New Orleans

76107

Helios CR, Inc Fort Worth, Fort Worth

77064

DM Clinical Research, Tomball

77081

DM Clinical Research, Houston

78215

Sun Research Institute, San Antonio

78613

Velocity Clinical Research, Austin, Cedar Park

85704

Noble Clinical Research, Tucson

90211

Cedars-Sinai Medical Center/Carbon Health, Beverly Hills

92120

Acclaim Clinical Research, San Diego

98104

University of Washington Virology Research Clinic, Seattle

02215

Fenway Health, Boston

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY

NCT06033261 - A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | Biotech Hunter | Biotech Hunter